WELICHEM BIOTECH INC.
Welichem Biotech Inc. is a clinical stage biotech company engaging in the discovery and
development of novel small molecule therapeutics for unmet medical needs. Before 2012, the
Company was dedicated to research and development of its novel anti-inflammatory drug
candidate, WBI-1001 and its derivatives. WBI-1001 was a novel anti-inflammatory agent
developed by the Company as a topical treatment for inflammatory skin diseases such as
psoriasis and atopic dermatitis. Four clinical studies were completed by the Company using
WBI-1001 creams for the treatment of atopic dermatitis and psoriasis. In July 2012, the WBI-
1001 technology was acquired by Stiefel, A Glaxo Group Limited (GSK) company, for further
development, regulatory approval, and commercialization.
Welichem's core strength has been early stage drug discovery and development since its
incorporation. In the past, the Company has been successful in advancing drug compounds to
clinical proof of concept stages and partnering with a pharmaceutical company to maximize the
value of the technology. Our experience allows us to move rapidly from early stage drug
discovery and development to clinical proof of concept and collaborate with strategic partners
for later stage of commercialization of our drug candidates.